triSure NIPT and Carrier Screening

Unique NIPT test integrating mother's carrier screening in one blood draw: 25 chromosomes, 18 carrier diseases.

More than 2,500 obstetricians recommend the triSure test to pregnant women

triSure - Non-invasive prenatal testing (NIPT)

The story of triSure - Gene Solutions' comprehensive NIPT (Non-invasive Prenatal Testing) solutions for all OBGYNs and pregnant women. triSure NGS-based screening products line covers from fetus basic trisomy, mother's carrier integration to single-gene disorders, with validated notable accuracy and unique post-test support.

The uniqueness of triSure algorithm and technical process.

triSure assay with integrated mothers’ recessive diseases procedure is validated by peer-reviewed publication.^()
triSure is the NIPT test that reduces the need for amniocentesis, 25 times more than other biochemical tests.^()
The triSure algorithm uniquely distinguishes between fetal and maternal DNA, aiding in the recognition of maternal mosaicism and fetal abnormalities to enhance test accuracy and minimize false positive cases.^()

(*) International publication “Establishing and validating non-invasive prenatal testing procedure for foetal aneuploidies in Vietnam”.

(**) Published in the Vietnamese Medical Journal “Investigate positive predictive values of NIPT triSure noninvasive prenatal test in medical practice” by Patricia AT, et al (2016); “Noninvasive prenatal testing in the general obstetric population: clinical performance and counselling considerations in over 85,000 cases”, Prenatal Diagnosis, 36, 237 243 & Petersen AK, et al. (2017). “PPV estimates for cell-free noninvasive prenatal screening from data of a large referral genetic diagnostic laboratory”, Am J Obstet Gynecol; 217:691. e1-6.

(***) International publication “Reducing false positive rate of foetal monosomy X in non invasive prenatal testing using a combined algorithm to detect maternal mosaic monosomy X”.

Benefits of trisure NIPT

Early screening for serious and common birth defects in the fetus as well as common recessive genetic diseases for mothers.

Performed at nine weeks or more of pregnancy and is recommended as the first test for pregnant women.

Sensitivity and specificity >99% can replace biochemical tests such as double test.

Early screening for timely intervention or a better pregnancy management plan, appropriate delivery management, postnatal care and preparation for the next pregnancy.